Certainly the committee will be visiting the discussion at the appropriate time.
We can signal that, as Dr. Berthiaume went through, there has been an evolution in how we look at the post-market. The requirement for adverse drug reaction reporting has been in the regulations for a very long time, so that has been happening. Some of the shifting is a question about who should be doing the reporting, what is the quality, what is the frequency, and which institutions should be involved. That has been the recent policy work.